Welcome to the Breakthru Podcast. I'm John "Baseball Buddha" Reimer, and in today’s episode, we're zooming out from the micro to the macro of the gene and cell therapy industry.

We're thrilled to share the insights from a recent visitor to Xiogenix, Grant Holley, the Director of Science & Education at the ASGCT. Grant is deeply entrenched in the narratives that are shaping the future of this industry, not just from a scientific standpoint, but from a regulatory, educational, and provider perspective as well.

Our discussion veered into the intricate workings of the industry, including the vital role ASGCT plays in pioneering education and support for professionals navigating this complex landscape. We went beyond the nuts and bolts of technology to address the broader hurdles we face—regulatory challenges, the FDA’s intricate approval process, and the market dynamics that companies like Xiogenix are actively engaging with as we introduce new technologies.

The path for innovators isn't just about creating; it’s about enabling. And for therapies and technology providers alike, the journey from concept to market is a narrative filled with both promise and perseverance.

In this candid conversation, we lay out what it takes for new technologies and therapies to move through the pipeline, the realities of bringing groundbreaking advancements like Xiogenix's Ares System to the clinical setting, and how these efforts intersect with the work of organizations like ASGCT.

Whether you're a healthcare professional, someone interested in the business of biotech, or just keen to hear a behind-the-scenes look at the field, this episode offers valuable perspectives you won't hear anywhere else.